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Abstract
Noninvasive imaging of lysosomes will be useful 1) to elucidate the role of lysosomal parameters in cancer, 2) to
diagnose malignant lesions, and 3) to evaluate future lysosome-targeted anticancer therapies. Lysosome-specific
labeling of glucosamine-bound near-infrared (NIR) fluorescent probes, IR-1 and IR-2, but not control probe IR-15
without the glucosamine moiety, was observed by fluorescence microscopy in human breast epithelial cell lines.
Lysosome labeling and tumor specificity of these NIR probes were investigated by dynamic optical imaging and
immunofluorescence staining in human breast tumor xenografts. IR-1 and IR-2 demonstrated faster lysosome
labeling rates in highly aggressive MDA-MB-231 and MDA-MB-435 cells compared with less aggressive MCF-7
and nontumorigenic MCF-12A cells. IR-1 and IR-2, but not IR-15, accumulated in human MDA-MB-231, MDA-
MB-435, and MCF-7 breast tumor xenografts in vivo. IR-2 demonstrated the highest maximum fluorescence
and tumor/normal tissue ratios in all tumor models. Specific lysosome labeling from IR-2 in vivo was validated by
colocalization of the NIR fluorescence with CD63 immunofluorescence in tumor sections. IR-1 and IR-2 demon-
strated high lysosome-labeling ability and breast tumor–targeting specificity in vitro and in vivo. They are promising
for diagnosing malignant lesions and may provide a means for evaluating and monitoring future lysosome-targeted
anticancer therapies.
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Introduction
Lysosomes are membranous organelles found in mammalian cells.
For a long time, they were considered to be a cell dump station, ex-
clusively involved in the degradation of excess or worn out organelles,
food particles, and engulfed viruses or bacteria [1]. The lysosomal
lumen is more acidic (≈pH 4.5) than the cytosol (≈pH 7.0) and con-
tains different types of proteases, including the family of cathepsins
[2,3]. For example, cathepsins B, L, and D, which are secreted into
the extracellular space, actively participate in the digestion of extra-
cellular matrix, thereby enabling the migration, invasion, and metas-
tasis of cancer cells [3,4]. Lysosomes in cancer cells demonstrate
significantly different morphology and trafficking compared to lyso-
somes in normal cells [5]. Our previous studies revealed that, under
conditions of acidic extracellular pH, as frequently found in the
tumor microenvironment [6], human breast epithelial cells with a
high degree of malignancy exhibited larger lysosome sizes, decreased
lysosome number, and increased nucleus–lysosome distances than
weakly metastatic cells [7]. Mohamed and Sloane [8] also observed
that lysosomes in cancer cells at the invasive edges of tumors redis-
tributed from perinuclear to peripheral regions, which may be asso-
ciated with altered lysosomal trafficking in these cells.
Apart from tumor progression, lysosomes have also been implicated
in the lysosomal cell death pathway [5]. Cathepsins released into the
cytosol on lysosomal membrane permeabilization can trigger a caspase-
independent and Bcl-2–insensitive apoptosis-like cell death pathway
in apoptosis-resistant cells, which may provide a new therapeutic
strategy for tumors that are resistant to traditional chemotherapy
[9]. Groth-Pedersen et al. [10] demonstrated that an early increase
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in the individual lysosomal volume and in the total lysosomal compart-
ment followed by lysosomal rupture was observed in this cathepsin-
mediated apoptosis-like cell death pathway. Therefore, the ability to
noninvasively image lysosome morphology and trafficking will be ex-
tremely useful 1) to elucidate the role of lysosomal parameters in
cancer invasion and metastasis, 2) to provide a means of diagnosing
malignant lesions in their early stages, and 3) to evaluate real-time
therapeutic response by monitoring lysosomal parameters in future
lysosome-targeted anticancer therapies [11–13].
Optical imaging is an emerging noninvasive diagnostic imaging
modality, which offers advantages including nonionizing radiation,
high sensitivity, low cost, and possibility of real-time image-guided
surgical procedures [14,15] compared with conventional techniques
such as magnetic resonance imaging and positron emission tomogra-
phy. Near-infrared tomographic breast imaging demonstrated clinical
potential because breast tissue can be easily interrogated by direct
contact with NIR sources and detectors. Optical breast imaging stud-
ies have validated the high sensitivity for NIR tomographic imaging
of intrinsic contrast, and several clinical trials are currently ongoing
[16,17]. For future applications of clinical optical imaging, probes
that are emissive in the near-infrared region (NIR) of 700 to 900 nm
are currently being developed [18–22]. The NIR region is advanta-
geous for in vivo optical imaging because background from tissue
autofluorescence and absorption from intrinsic chromophores are
low, allowing NIR light to penetrate several centimeters into hetero-
geneous tissues [23].
6-[N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-6-deoxyglucose
(2-NBDG) [24], pyro-2DG [25], and polyvalent carbocyanine
molecular beacons [26], in which fluorophores functionalize the
2-position of glucosamine, were selectively delivered to and accu-
mulated in tumors, possibly due to enhanced glycolysis and an up-
regulation of the glucose transporter (GLUT)/hexokinase pathways
in cancer cells compared to nonneoplastic cells [27]. Our previous
work showed that fluorophores functionalized at the 6-position of
glucosamine can specifically label the lysosomes of human mammary
epithelial cells (HMECs) in vitro [28,29]. Most likely, these modified
glucosamines can be used as substrates in cancer cells to biosynthesize
highly glycosylated lysosomal proteins [29]. We recently prepared two
novel NIR probes: IR-1 and IR-2, in which the NIR chromophore
was covalently bound to the 6-position of glucosamine through two
different linkers [30] (see Figure 1A). These two NIR probes exhib-
ited high quantum yields, low cytotoxicity, reversible pH-dependent
fluorescence in the case of IR-2, low aggregation tendency, and ef-
ficient cellular uptake in HMEC cultures. In this work, we tested
lysosome-labeling capabilities of these two NIR probes in four HMEC
lines. The biodistribution, tumor-targeting specificity, and lysosome-
labeling abilities of IR-1 and IR-2 in mice bearing human MDA-
MB-231, MDA-MB-435, or MCF-7 breast tumor xenografts were
also studied. For comparison, control NIR probe IR-15 without cova-
lently bound glucosamine moiety was also evaluated.
Materials and Methods
Preparation of IR-1, IR-2, and Control Probe IR-15
IR-1, IR-2, and IR-15 were synthesized as previously described
[30]. Briefly, the hydroxyl-group in the 6-position of glucosamine
was converted to a primary amine, which was reacted with 3-(4-
hydrophenyl) propionic NHS-ester or 3-(4-iodobutoxy)-phenyl ace-
tate, to offer the two linkers with different lengths. The etherification
between the phenol moiety of the linkers and the allyl chloride of
IR-783 (Sigma-Aldrich, St. Louis, MO) gave IR-1 and IR-2. Similarly,
the control molecule IR-15 was prepared by etherification between
phenol and IR-783.
Cell Culture
Four HMEC lines representing different grades of malignancy were
obtained from the American Type Culture Collection (Rockville, MD).
MCF-12A, a spontaneously immortalized nontumorigenic cell line,
was cultured in DMEM-Ham’s F12 medium (Invitrogen, Carlsbad,
CA) supplemented with 10% horse serum, 100 U/ml penicillin
and 100 μg/ml streptomycin (Pen/strep), epidermal growth factor
(20 mg/ml), cholera toxin (100 ng/ml), insulin (10 ng/ml), and hydro-
cortisone (500 ng/ml). MCF-7, an estrogen-sensitive weakly aggressive
breast cancer cell line, was cultured in Eagle’s minimum essential
medium (Mediatech, Herndon, VA) supplemented with 10% fetal
bovine serum and antibiotics. The highly aggressive HMEC lines
MDA-MB-231 and MDA-MB-435 were maintained in RPMI-1640
medium (Invitrogen) supplemented with 10% fetal bovine serum,
100 U/ml penicillin, and 100 μg/ml streptomycin (Invitrogen). All
cells were grown as monolayers in 75-cm2 culture flasks (Sigma-
Aldrich) in a humidified atmosphere of 5% CO2 in air at 37°C and
were harvested when they reached 80% confluence to maintain ex-
ponential growth.
Breast Cancer Xenograft Models
All in vivo studies were performed in compliance with the National
Institutes of Health (NIH) and institutional guidelines established
for Animal Core Facilities at the Johns Hopkins University. MDA-
MB-231 and MDA-MB-435 tumor xenografts were derived by in-
oculating 1 × 106 MDA-MB-231 or MDA-MB-435 cells in 0.05 ml
of Hank’s balanced salt solution (HBSS) into the upper left thoracic
mammary fat pad of female severe combined immunodeficiency
(SCID) mice anesthetized with a ketamine/acepromazine mixture.
Estrogen-dependent MCF-7 tumor growth was supported by a
0.72-mg 17β-estradiol 60-day release pellet (Innovative Research of
America, Sarasota, FL) implanted subcutaneously into the back of
mice 1 week before tumor inoculation (1 × 106 cells/mouse). Tumor
volumes used in the study were 200 to 300 mm3 and usually devel-
oped within 5 weeks of inoculation for MDA-MB-231 and MDA-
MB-435 and within 2 months for MCF-7 tumors.
Fluorescence Microscopy
All fluorescence microscopic images were obtained with an Olympus
IX81 inverted microscope with epifluorescence and phase contrast optics
using 60×/1.42 NA or 100×/1.40 NA oil immersion lenses (Olympus
America Inc., Center Valley, PA). The microscope was equipped
with a Hamamatsu C9100 EM-CCD digital camera (Hamamatsu
Photonics, Bridgewater, NJ) and IPLab 4.0 software (Scanalytics
BD Biosciences, Rockville, MD). Near-infrared fluorescence was mea-
sured using an indocyanine green (ICG) filter cube (Chroma Set
41030; Chroma Technology Corp., Rockingham, VT; excitation:
775 ± 50 nm and emission: 845 ± 55 nm). Cy3 fluorescence was de-
tected using a Texas Red filter cube (Olympus America Inc.). Phase
contrast, NIR, and Alexa Fluor-488 or Cy3 fluorescence images were
acquired of the same field of view (FOV).
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Immunofluorescence Staining
Human mammary epithelial cells were grown on glass chamber
slides (Nalge Nunc, Naperville, IL) to 70% to 80% confluence. A
concentration of 20 μM of IR-1, IR-2, or IR-15 in culture medium
was added to the cells and was incubated for 8, 24, or 48 hours. The
treated cells were washed twice with ice-cold phosphate-buffered
saline (PBS) and fixed with 4% paraformaldehyde in PBS for 20 min-
utes on ice. Cells were washed three times and incubated with 5%
Figure 1. Cellular uptake and localization of NIR probes in live HMEC lines. (A) Chemical structures of IR-1, IR-2, and control molecule
IR-15 [30]. (B) NIR fluorescence and phase contrast microscopy images of live MDA-MB-231, MDA-MB-435, MCF-7, and MCF-12A cells
after incubation with 20 μM IR-1 for 24 hours. Scale bar, 15 μm. (C) Fluorescence and phase contrast microscopy images of live MDA-
MB-231 cells after exposure to 20 μM IR-1, IR-2, and IR-15 for 24 hours. Scale bar, 20 μm. Selected image areas highlighted by a square
were enlarged as shown in the right panel of (C). Arrows point the vesicles in the periphery of MDA-MB-231 cells. Scale bar, 10 μm. All
images were acquired with a 60× oil immersion lens.
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normal donkey serum in PBS for 30 minutes at room temperature.
Cells were incubated with a 1:200 dilution (dilution buffer consist-
ing of 0.5% bovine serum albumin and 0.01% sodium azide in PBS)
of a monoclonal antibody against CD63 (Abcam, Cambridge, MA)
overnight at 4°C. After washing three times with dilution buffer, cells
were incubated with a 1:50 dilution of a Cy3-conjugated donkey
anti–mouse antibody (Jackson ImmunoResearch Laboratories, West
Grove, PA) for 1 hour at room temperature and washed three times
with PBS. Cells were mounted with Faramount aqueous mounting
medium (Dako, Carpinteria, CA) and ready for imaging.
Lysosome Labeling in Live Cells
Human mammary epithelial cells were seeded on 35-mm glass-
bottom culture dishes (14-mm microwell; MatTek, Ashland, MA).
After reaching 70% to 80% confluence, culture media containing
0.1 mg/ml Alexa Fluor-488–labeled dextran with a molecular weight
of 10 kDa (Molecular Probes, Eugene, OR) was added and incubated
for 3 hours. Cells were washed three times with HBSS and con-
tinually incubated in normal culture media for 16 hours to achieve
lysosome labeling from dextran through the endocytic pathway. After
washing three times with HBSS, media with 20 μM IR-1, IR-2, or
IR-15 was added, and incubated for another 8 to 24 hours. After
washing twice with HBSS, phenol red–free culture media was added
to the cells before microscopy studies.
Blocking Studies of Cellular Uptake of NIR Dyes In Vitro
MDA-MB-231 cells cultured in 35-mm glass-bottom culture dishes
were preincubated with regular medium, medium supplemented with
50 mM D-glucose, or 1, 2, or 5 mM glucosamine for 1 hour at 37°C,
respectively. Glucosamine concentrations greater than 5 mM proved to
be toxic and caused cell death. IR-1 or IR-2 with a final concentration
of 20 μMwas added, and the cells were further incubated for 24 hours
at 37°C. At the end of incubation, cells were washed three times with
ice-cold HBSS and subjected to microscopy imaging.
In Vivo and Ex Vivo Optical Imaging Studies
Optical imaging was performed on a Xenogen IVIS 200 small
animal imaging system (Xenogen, Alameda, CA) equipped with an
indocyanine green (ICG) band pass filter set (810–875 nm). All fluo-
rescence images were acquired with 0.1-second exposure time (FOV,
12.8 cm; f/stop, 4; bin, high resolution), and fluorescence intensity
was scaled as units of photons per second per centimeter squared
per steradian (p/s/cm2/sr). Before imaging, mice were anesthetized,
and the fur on the tumor and a large surrounding skin area were shaved
to reduce light absorbance and autofluorescent scattering. Serial bright-
field photographs and fluorescence images were acquired before and at
multiple time points after systemic injection of IR-1, IR-2, or IR-15
(100 nmol/mouse) through the tail vein. During in vivo imaging,
the tumor and its surrounding normal tissue were chosen as two dis-
tinct regions of interest (ROIs). The time-dependent fluorescence in-
tensities in these ROIs were quantified and analyzed by using Living
Image 2.5 software (Xenogen). Tumor/normal tissue ratios (T/N )
were calculated by comparing the average fluorescence intensities in
the tumor ROI and its surrounding normal tissue ROI. T/N values
at selected time point after injection were normalized to its cor-
responding value measured preinjection. At the end of in vivo imaging
studies, the mouse was scarified, and tumor and thigh muscle were
excised, sectioned with a thickness of 1.0 mm with a tissue slicer
(Braintree Scientific Inc., Braintree, MA), and imaged simultaneously.
The fluorescence intensities of ex vivo tumor sections were quantified
in ImageJ (NIH, Bethesda, MD) and normalized to the value of
the muscle.
Biodistribution Studies
Biodistribution studies of IR-1, IR-2, and IR-15 were performed
as previously reported [16,31]. Tumor-bearing mice were scarified at
24 hours after intravenous injection of IR-1, IR-2, or IR-15 (100 nmol/
mouse). The tumor and major organs were excised and sliced into
3-mm-thick pieces to minimize differences in tissue thickness and
depth-dependent nonlinear fluorescence emission. Tissue slices (three
to four slices per organ) from at least three mice were imaged with the
Xenogen IVIS 200 imaging system. Average fluorescence intensities of
tissue sections were quantified by using ImageJ (NIH) and normalized
to the value of the thigh muscle from the same animal.
Statistical Analysis
All data are presented as mean ± SD of at least three experiments.
We analyzed statistical differences by Student’s t test (Microsoft Excel
2002, Microsoft Corp, WA). Statistical significance was defined at
the level of P < .05 (two-tailed).
Results
Cellular Uptake of NIR Probes Was Not Blocked By
D-Glucose and Glucosamine in HMEC Lines
Cellular uptakes of IR-1, IR-2, and control molecule IR-15 were
investigated in HMECs. A concentration of 20 μM of IR-1 and IR-2
was shown to label HMECs efficiently without causing alterations
in cell morphology and doubling time. Figure 1B shows fluorescence
images of MDA-MB-231, MDA-MB-435, MCF-7, and MCF-12A
cells after treatment with 20 μM IR-1 for 24 hours at 37°C. Clear
vesicular structures were predominately located in the perinuclear re-
gion of cells, and the punctuate staining pattern persisted with increas-
ing fluorescence intensity after incubation for 48 hours. Incubation
with IR-2 resulted in labeling similar to IR-1 (Figure 1C ). However,
the intracellular staining pattern from control molecule IR-15 was quite
different. As shown in Figure 1C, clear vesicular structures labeled by
IR-1 or IR-2 were enriched in the perinuclear area, and a few of them
were also found in the periphery of MDA-MB-231 cells. In con-
trast, IR-15 resulted in a homogenously distributed granular staining
pattern accompanied by a strong fluorescence background throughout
the cytoplasm. To elucidate the cellular uptake mechanism of the
glucosamine-bound NIR probes, MDA-MB-231 cells were pre-
incubated with 50 mM D-glucose, or 1, 2, or 5 mM glucosamine
before and during treatment with IR-1 or IR-2. The typical intracel-
lular vesicular staining pattern resulting from IR-1 or IR-2 was not
affected by either 50 mM D-glucose or up to 5 mM glucosamine
(data not shown).
Glucosamine-Bound NIR Probes Label Lysosomes
in HMEC Lines
Lysosome labeling from glucosamine-bound NIR probes in live cells
was identified by colocalization of the NIR probe with Alexa Fluor-
488–conjugated dextran, which was used as a long-term lysosomal
fluorescence marker in live cells [32]. Fluorescence microscopy images
of live MDA-MB-231 cells after labeling with fluorescent dextran and
NIR probes IR-1, IR-2, or IR-15 are shown in Figure 2A. Whereas
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both IR-1 and IR-2 demonstrated excellent colocalization with dextran,
only partial colocalization between IR-15 and dextran was observed.
To further assess the lysosomal specificity of these NIR probes, HMECs
were treated with 20 μM of each NIR probe for 8, 24, or 48 hours
before fixation and immunofluorescence staining with CD63 anti-
body. CD63 is a glycoprotein in the lysosomal membrane and a well-
established lysosomal marker [33]. As shown in Figure 2B, in addition to
the yellow colocalized vesicles in the perinuclear region, single-labeled
red vesicles from NIR fluorescence were found in the periphery of
MDA-MB-231 cells after incubation for 8 hours. In contrast to IR-1,
nonspecific staining from IR-15 resulted in a strong fluorescence back-
ground distributed throughout the entire cytoplasm. Compared with
the 8-hour incubation, a higher degree of colocalization was observed
in cells treated with IR-1 or IR-2 for 24 hours (Figure 2C ). However,
this phenomenon was barely observed in the cells incubated with IR-15.
Figure 2D shows the time-dependent colocalization coefficients be-
tween IR-1, IR-2, or IR-15 and the lysosome marker CD63 in the four
HMEC lines. IR-1 and IR-2 demonstrated similar lysosome-labeling
Figure 2. Glucosamine-bound NIR probes demonstrated lysosome specificity in HMEC lines. (A) Representative fluorescence images of
live MDA-MB-231 cells treated with the lysosome marker Alexa Fluo-488–conjugated dextran (50 μg/ml) and subsequently with 20 μM
IR-1, IR-2, or IR-15 for 24 hours. The NIR fluorescence is displayed in red, and the Alexa Fluo-488 fluorescence is displayed in green.
Colocalization of NIR probe and dextran is indicated by yellow in the merged image. Scale bar, 20 μm. These images were acquired with
a 60× oil immersion objective. (B) Representative fluorescence images of MDA-MB-231 cells that were treated 20 μM IR-1 or IR-15
for 8 hours, fixed, and followed by immunofluorescence staining with CD63 antibody. These images were acquired with a 100× oil im-
mersion lens. The NIR fluorescence is displayed in red, and the CD63 immunofluorescence is in green. Yellow indicates colocalization of
NIR probe and CD63. Arrows point to single-stained vesicle structures at the periphery of cells. Scale bar, 15 μm. (C) Representative fluo-
rescence images of MDA-MB-231 cells that were treated with 20 μM IR-1, IR-2, or IR-15 for 24 hours, fixed, and followed by immuno-
fluorescence staining with CD63 antibody. Arrows point to single-stained vesicle structures. Scale bar, 15 μm. (D) The colocalization
coefficients of NIR fluorescence with CD63 immunofluorescence were quantified in HMECs after incubation with NIR probe for 8, 24,
or 48 hours. The colocalization coefficients were determined from five to six randomly selected images. All images were acquired with
a 40× oil immersion lens, and totally 120 to 200 cells were assessed. Data represent a minimum of three independent experiments. Data
points indicate the mean; bars, SD.
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behaviors and exhibited much faster lysosome incorporation rates in the
highly aggressive MDA-MB-231 and MDA-MB-435 cell lines as com-
pared with less aggressive MCF-7 and nontumorigenic MCF-12A cells
(Figure 2D). The colocalization coefficient of IR-15 with CD63 was
much lower than that of IR-1 and IR-2 with CD63, and it was inde-
pendent of the incubation time in all HMEC lines.
Glucosamine-Bound NIR Probes Demonstrated
Tumor-Targeting Specificity In Vivo
Whole-body dynamic optical imaging of mice implanted with
human breast tumor xenografts was performed after systemic admin-
istration of NIR probes. Figure 3 shows representative in vivo NIR
fluorescence images of MDA-MB-231 tumor–xenografted mice be-
fore and at 5, 15, 30, 45, 60, 90, 120, 240, 480, and 1440 minutes
after intravenous administration of IR-1, IR-2, or IR-15 (100 nmol/
mouse). Specific uptake of IR-1 and IR-2 into the tumor was appar-
ent from highly NIR fluorescent tumors compared to its surrounding
normal tissues. However, no remarkable fluorescence was observed in
the tumor after the injection of IR-15. At 24 hours after injection of
NIR dyes, significant fluorescence was still detected in tumors treated
with IR-1 and IR-2. For IR-15, obvious fluorescence was clearly de-
tected in the mouse abdomen but not in the tumor. Near-infrared fluo-
rescence was also detected in the ear, tail, and extremities of the mouse
at early time points after administration as evident from Figure 3. Fluo-
rescence intensities in MDA-MB-231, MDA-MB-435, and MCF-7
tumors as a function of time are depicted in Figure 4A. Notably,
IR-2 demonstrated higher maximum fluorescence intensity and longer
residence lifetime than IR-1 and IR-15 in all tumor types. For example,
in MDA-MB-231 tumor xenografts, the maximum fluorescence inten-
sities introduced by IR-1, IR-2, and IR-15 were 8.4 ± 0.45, 9.5 ± 0.51,
and 4.6 ± 0.33 × 1011 p/s/cm2/sr, and the corresponding t1/2 (the time
at which the fluorescence intensity in the tumor was reduced to half of
its maximum value) were 2.5, 24, and 10.5 hours, respectively. Near-
infrared fluorescence intensities in the tumor area also depended on the
tumor type. In MCF-7 tumors, the maximum fluorescence intensity
resulting from IR-1 or IR-2 was three to five times lower than that
in MDA-MB-231 and MDA-MB-435 tumors. Time courses of the
fluorescence intensity ratios between tumor and surrounding normal
tissue (T/N value) after systemic administration of NIR probe are
shown in Figure 4B. IR-2 demonstrated higher T/N values than IR-1
and IR-15 at all time points in all three tumor models. In contrast,
the T/N values of IR-15 fluctuated around 1.0 for most of the time after
administration, demonstrating that IR-15 is not tumor-specific.
Figure 5, A and B, shows typical NIR fluorescence images, and
superimposed photographic and color-coded NIR fluorescence images
of SCID mice bearing MDA-MB-435 tumor xenografts, respectively,
Figure 3. IR-1 and IR-2, but not IR-15, demonstrated targeting specificity to MDA-MB-231 breast tumor xenografts in the in vivo dynamic
optical imaging studies. In vivo optical images of human MDA-MB-231 breast tumor–bearing mice before and after administration of
100 nmol of IR-1, IR-2, or IR-15. (a) Superimposed photography and color-coded fluorescence image of mice before injecting NIR
probes. (b−k) Representative color-coded fluorescence images of mice at selected time points after intravenous injection of IR-1,
IR-2, or IR-15. (l) Representative NIR fluorescence images of mice at 24 hours after injection of IR-1, IR-2, or IR-15. The arrows point
the position of tumors in the mice. All images were acquired on a Xenogen IVIS 200 small animal imaging system with an ICG excita-
tion and emission filter set. FOV, 12.8 cm; f/stop, 4; bin, high resolution; exposure time, 0.1 second. Arrows point the position of the
tumor xenograft.
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at 24 hours after injection of IR-1, IR-2, or IR-15. Comparable to the
MDA-MB-231 tumor model, IR-1 and IR-2 resulted in efficient tu-
moral NIR fluorescence enhancement in MDA-MB-435 tumor xeno-
grafts. The most intense fluorescence from IR-15 was located in the
pelvic area, and originated from the liver as evident from the ex vivo
studies. The tumors shown in Figure 5, A and B, were excised and sec-
tioned at 24 hours after injection. Fluorescence imaging of these fresh
tumor sections (Figure 5C ) revealed a heterogeneous intratumoral dis-
tribution of all NIR probes, with IR-2 exhibiting the most intense fluo-
rescence. The biodistribution of IR-1, IR-2, and IR-15 at 24 hours after
injection was investigated in tumor-xenografted mice as shown in
Figure 5D. Tumor uptakes of IR-1 and IR-2 were two- to four-fold
higher than that of IR-15. Apart from the tumor, IR-1 and IR-2 were
also retained in organs including liver and intestine, but little of these
dyes were detected in muscle, brain, spleen, and blood. IR-15 pre-
dominately accumulated in the liver, in which the average fluorescence
intensity was eight times higher compared to that of IR-1 or IR-2.
IR-15 also demonstrated higher fluorescence intensity in the gastro-
intestinal system compared to IR-1 or IR-2.
Glucosamine-Bound NIR Probes Label Lysosomes
in Tumor Xenografts
The lysosome-labeling ability of these NIR probes was assessed by
CD63 immunofluorescence staining of tumor sections after in vivo
imaging studies. As shown in Figure 6, A and C, partial and more
complete colocalization between IR-2 and CD63 was demonstrated
at 8 and 24 hours after injection, respectively. However, NIR fluo-
rescence from IR-1 (data not shown) and IR-15 was much lower in
tumor sections than that from IR-2 (Figure 6B). The colocalization
coefficient of each NIR probe in MDA-MB-231 tumor xenografts
was quantified as presented in Figure 6D. IR-2 exhibited significantly
higher colocalization coefficients than IR-15 at both 8 and 24 hours
after injection. Comparable values for the ex vivo fluorescence co-
localization between IR-2 and CD63 were also obtained in MDA-
MB-435 and MCF-7 breast tumor xenografts (data not shown).
Discussion
We synthesized two glucosamine-bound NIR fluorescent probes
and evaluated their lysosomal-labeling capability and tumor-targeting
specificity in vitro and in vivo. These probes can also potentially be
used for in vivo subcellular lysosome imaging with minimally invasive
intravital microscopy. The ability to optically image lysosomes in vivo
will further our understanding of the role of lysosomes in tumor in-
vasion and metastasis [7], provide a future means of diagnosing ma-
lignant cancers, and help in developing lysosome-targeted anticancer
therapies [11–13] that exploit the lysosomal cell death pathway [5].
2-[18F] Fluoro-2-deoxy- D-glucose (FDG) has been successfully
used in positron emission tomography to image tumors in the clinic
for more than two decades [34]. FDG accumulates in tumors due
to the upregulated GLUTs in cancer cells and the lacking hydroxyl
group at the 2-position which prevents its further glycolysis [34].
Near-infrared probes that are analogous to FDG, such as pyro-2DG
[25], polyvalent carbocyanine beacons [26], and Cy5.5-2DG [35] also
demonstrated specific accumulation in various tumor xenograft mod-
els, although their uptake mechanism remains controversial. Func-
tionalization of fluorophore at the 6-position of glucosamine such as
6-NBDG demonstrated a similar cellular uptake through GLUT1 as
Figure 4. Quantification and kinetics of in vivo targeting characteristics of NIR probes in MDA-MB-231, MDA-MB-435, and MCF-7 tumor-
bearing SCID mice. (A) Time course of in vivo fluorescence intensities in three different types of breast tumor xenografts measured as
units of p/s/cm2/sr. Near-infrared probes were intravenously injected with a dosage of 100 nmol/mouse. t1/2 represents the time at which
the tumoral fluorescence intensity has decreased to half of its maximum value. (B) Time course of T/N calculated for the three types of
breast tumor xenografts after intravenous injection of IR-1, IR-2, or IR-15 (100 nmol/mouse). T/N values were normalized to preinjection
background levels measured before NIR probe injection. Data are expressed as mean ± SD (n = 3 mice per group).
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2-NBDG [36], indicating that 6-position–modified glucosamines such
as IR-1 and IR-2 may also be taken up through GLUT1. However,
our in vitro blocking studies showed that the cellular uptake of IR-1
and IR-2 in MDA-MB-231 cells was not significantly blocked by
50 mM D-glucose, which suggests that IR-1 and IR-2 are not taken up
into breast cancer cells through GLUTs. The uptake of these two NIR
probes was not blocked in the presence of up to 5 mM glucosamine
either. Higher concentrations of glucosamine could not be tested in
these blocking studies because of its toxicity at higher concentrations.
The lysosome-labeling capability of IR-1 and IR-2 in HMECs cul-
tures was demonstrated by colocalization of NIR fluorescence with
fluorescence from lysosomal markers in live and fixed cells. The faster
lysosome-labeling rates of IR-1 and IR-2 observed in the two highly
aggressive MDA-MB-231 and MDA-MB-435 breast cancer cell lines
compared to the less aggressive MCF-7 cell line and nontumorigenic
MCF-12A cell line may be explained by differences in protein glyco-
sylation, which is important in tumorigenesis and progression to me-
tastatic disease [37,38].
To elucidate the role of the glucosamine moiety for lysosome- and
tumor-labeling specificity, we compared IR-1 and IR-2 to a control
NIR probe, IR-15, in which the glucosamine was replaced with a bio-
chemically inert benzene ring. In contrast to the clear vesicle structures
predominately found in the perinuclear region of cells treated with IR-1
or IR-2, a homogenously granular staining pattern with a strong fluo-
rescent background in the cytoplasm was observed in the cells exposed
to IR-15. The time independence of the partial IR-15 colocalization
with lysosomes in HMECs further supports that glucosamine-bound
IR–1/2 and control molecule IR-15 might be taken up by entirely dif-
ferent cellular transport and trafficking pathways. It is obvious that the
glucosamine moiety in IR-1 and IR-2 was crucial in conferring lyso-
some specificity as evident from the high degree of colocalization of
IR-1 and IR-2 with lysosomal markers.
Our in vivo experiments demonstrated an excellent tumor specific-
ity of the glucosamine-bound NIR probes IR-1 and IR-2, which was
apparent from high tumoral fluorescence intensity and T/N values
after systemic administration in breast tumor–xenografted mice. Al-
though IR-1 and IR-2 demonstrated similar lysosomal labeling prop-
erties in the cell culture studies, our dynamic in vivo imaging studies
indicated that IR-1 underwent a more rapid excretion rate in these ani-
mal models, possibly leading to the lower T/N values when compared
Figure 5. Glucosamine-bound NIR probes IR-1 and IR-2 demonstrated targeting specificity to human MDA-MB-231, MDA-MB-435, and
MCF-7 breast tumor xenografts. (A) Representative NIR fluorescence image of MDA-MB-435 tumor bearing mice at 24 hours after
injection of 100 nmol IR-1, IR-2, or IR-15. (B) Superimposed photography and color-coded fluorescence image of the mice shown in
panel (A). Arrows point the position of the tumor xenograft; arrowheads point the position of the liver. (C) Representative ex vivo white
light, fluorescence, and color-coded fluorescence images of MDA-MB-435 tumor sections with a thickness of 1.0 mm at 24 hours after
injection of IR-1, IR-2, or IR-15 (100 nmol/mouse). (D) Biodistribution of IR-1, IR-2, and IR-15 in MDA-MB-231, MDA-MB-435, and MCF-7
tumor-bearing mice at 24 hours after systemic injection into the tail vein. The fluorescence intensities in the tissue sections were nor-
malized to that of muscle. Data are expressed as mean ± SD (n = 3 for each type of tumor xenograft).
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to IR-2. Structurally, the overall positive charges of IR-2 in the physi-
ological pH range may facilitate its association with negatively charged
albumin through electrostatstic binding, which may prolong its cir-
culation lifetime and result in evident fluorescence in the highly vas-
cularized ears, tail, and extremities of the mouse at early time points
after administration. Both IR-1 and IR-2 demonstrated three- to five-
fold higher fluorescence intensities in MDA-MB-231 and MDA-MB-
435 tumors compared to MCF-7 tumors at any given time point (0–
24 hours) after systemic administration. This result may be explained by
increased protein glycosylation in the highly aggressive MDA-MB-231
andMDA-MB-435 tumors as compared with the less aggressiveMCF-7
tumors [37,38]. Given the performance of IR-1 and IR-2 in the in vivo
studies, these glucosamine-bound NIR probes, especially IR-2, may not
only be used to diagnose breast tumors in their early stages but may also
provide a means of differentiating aggressive tumors from less aggressive
lesions by evaluating the fluorescence intensity in the tumor site. IR-15
without the glucosamine moiety did not demonstrate any tumor spec-
ificity in the three tumor xenograft models, and it predominantly accu-
mulated in the liver. As the liver is known to accumulate lipophilic
molecules [39,40], our data indicate that conjugating glucosamines with
multiple hydrophilic groups to NIR fluorophores can substantially im-
prove the pharmacokinetics and pharmacodynamic behavior of these
NIR fluorophores. The retention of IR-1 and IR-2 in the liver, kidney,
and gastrointestinal system was most likely due to the excretion of these
NIR probes through both the renal and hepatobiliary pathways because
NIR fluorescence was also detected in the urine and feces of these mice
at 24 hours after tail vein injection (data not shown). Lysosomal im-
munofluorescence staining revealed that IR-2 localized to the lysosomes
in human breast tumor xenografts after systemic administration. The
lysosome labeling from IR-2 in tumors, as identified by the colocal-
ization coefficient, was time-dependent and reached maximal values at
24 hours after injection. These combined ex vivo immunofluorescence
data suggest that the tumor specificity of IR-2 in vivomay partially result
from its efficient lysosome labeling.
In conclusion, both glucosamine-bound NIR probes IR-1 and IR-2
demonstrated efficient lysosome labeling in breast cancer cell cultures,
as well as excellent tumor-targeting specificity and lysosome labeling in
human breast cancer xenografts in vivo. IR-2 also provided very good
detection sensitivity and high T/N ratio. These probes will be ex-
tremely helpful in understanding the role of lysosome morphology
and trafficking in breast cancer invasion and metastasis in vivo. Moni-
toring lysosomal parameters using IR-1 and IR-2 may further provide
a means for early diagnosis of malignant lesions and for evaluating the
real-time response to lysosome-targeted or lysosome-affecting anti-
cancer therapies.
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